NCT05521438View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 23, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Netherton Syndrome
Interventions
DRUG

QRX003-2% Lotion

QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)

DRUG

QRX003-4% Lotion QAM

QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)

DRUG

Vehicle

Vehicle Lotion

DRUG

QRX003-4% Lotion BID

QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)

Trial Locations (5)

29425

RECRUITING

Site #3, Charleston

46250

RECRUITING

Site #4, Indianapolis

72218

RECRUITING

Site #2, San Antonio

92123

RECRUITING

Site #1, San Diego

02169

RECRUITING

Site #5, Quincy

Sponsors
All Listed Sponsors
lead

Quoin Pharmaceuticals

INDUSTRY

NCT05521438 - Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome | Biotech Hunter | Biotech Hunter